Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

zanamivir

zanamivir
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Relenza POWDER, INHALATION 5 mg      
Relenza SOLUTION, INTRAVENOUS      
VIEW MORE Neuramindase Inhibitors
CLASS
081828
Comments:

IV zanamavir (January 2014): This is the intravenous form of RELENZA and is currently available through investigational compassionate use for treatment of serious influenza illness. The drug will be used under an investigational compassionate use monitoring program, through the Anti-microbial Management Team. The physician must be registered to prescribe it and the Committee restricted its use to infectious disease physicians.

Reviewed: March 24, 2009 (RELENZA) and January 28, 2014 (IV zanamavir)

Last updated: Nov. 16, 2022
  • Formulary, Not Routinely Stocked: 5 mg/blister inhaler






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved